Conference Coverage

New cell-free DNA assays hold promise for lung cancer screening


 

REPORTING FROM ASCO 2018


Dr. Oxnard disclosed that he has a consulting or advisory role with AstraZeneca, Inivata, Boehringer Ingelheim, Takeda, Genentech/Roche, Novartis, Loxo Oncology, Ignyta, DropWorks, and GRAIL, and that he has patents, royalties, and/or other intellectual property with Chugai Pharmaceutical, Bio-Rad, Sysmex, and Guardant Health. The study was funded by GRAIL.

SOURCE: Oxnard GR et al. ASCO 2018. Abstract LBA8501.

Pages

Recommended Reading

FDA wants data on role of flavored tobacco products in youth initiation
MDedge Internal Medicine
Nivolumab helps some with advanced NSCLC reach 5-year mark
MDedge Internal Medicine
Bisphosphonate use linked with lower risk of lung cancer for never-smokers
MDedge Internal Medicine
EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Internal Medicine
Nivolumab shows promise in early-stage resectable NSCLC
MDedge Internal Medicine
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Internal Medicine
E-cigarette usage has changed
MDedge Internal Medicine
Palliative care may reduce suicide among lung cancer patients
MDedge Internal Medicine
Uptake of lung cancer screening is exceedingly low
MDedge Internal Medicine
A blood test to detect lung cancer inches toward the clinic
MDedge Internal Medicine